Ascletis Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASCLF research report →
Companywww.ascletis.com
Ascletis Pharma Inc. , a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus.
- CEO
- Jinzi Jason Wu
- IPO
- 2019
- Employees
- 231
- HQ
- Hangzhou, CN
Price Chart
Valuation
- Market Cap
- $1.76B
- P/E
- -36.39
- P/S
- 6937.25
- P/B
- 6.77
- EV/EBITDA
- -26.78
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 25.99%
- Op Margin
- -23853.94%
- Net Margin
- -17745.56%
- ROE
- -18.93%
- ROIC
- -24.90%
Growth & Income
- Revenue
- $1.98M · 53.99%
- Net Income
- $-350,592,985 · -16.50%
- EPS
- $-0.36 · -20.00%
- Op Income
- $-471,274,213
- FCF YoY
- 3.75%
Performance & Tape
- 52W High
- $2.50
- 52W Low
- $0.89
- 50D MA
- $2.03
- 200D MA
- $1.76
- Beta
- 0.47
- Avg Volume
- 679
Get TickerSpark's AI analysis on ASCLF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ASCLF Coverage
We haven't published any research on ASCLF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ASCLF Report →